Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
Amylyx(AMLX) Businesswire·2024-02-08 22:00Amylyx(AMLX) Businesswire·2024-02-08 22:00
R1Amylyx(AMLX) Businesswire·2024-02-08 22:00